Abstracts

Impact of CD4 Mimetics-Resistant Mutations on Susceptibilities to Anti-Env nMAbs

Background: CD4 mimic small compounds (CD4MCs), NBD-556 and its analogues inhibit the gp120-CD4 interaction and can also induce conformational changes in the gp120 architecture thereby exposing masked epitopes of neutralizing antibodies on the Env protein. In this study, we induced the CD4MCs resistant variants using primary isolate to elucidate the interactions between gp120 and CD4MCs,…

Characterising the Complex Mutational Pathways Associated With Maraviroc-Resistant HIV-1

Background: The drug maraviroc differs from other HIV-1 drugs as it binds the host cell coreceptor CCR5 as opposed to a virus protein. Lack of sensitivity to such entry-inhibitor drugs occurs primarily through emergence of pre-existing viruses that use the CXCR4 coreceptor, while genuine CCR5-antagonist resistance occurs through virus use of the drug-bound CCR5 coreceptor.…

M184I and M230I Minority Variants in ART-Naïve Patients Are Linked to APOBEC3G/F Activity

Background: In a recent multicohort European case-control study in ART-naive patients, presence of at least 1 IAS-2013 RT minority variant (MV) was associated to an increased risk of first-line NNRTI-containing treatment failure. Most prevalent MVs detected were V90I(4%), V106I(3%) ,V108I(3%), M184I(3%), M230I(2%) and all corresponding to G-to-A mutations. We evaluated whether these mutations could result…

Analyses of Accessory Mutations in HIV-1 Protease Reveal Interdependent Mechanisms of Resistance

Background: The HIV-1 protease is crucial to the maturation of budding virions. Low adherence to protease inhibitors due to toxicity cause both primary active site mutations, which result in a loss of enzymatic fitness, and accessory mutations, which restore fitness and stability of the enzyme, to arise. The contribution of accessory mutations in conferring drug…

Impact of Raltegravir/Elvitegravir Selected Mutations on Dolutegravir Cross-resistance

Background: Mutations at position 148 of HIV integrase (IN) represent a major mutational pathway leading to raltegravir (RAL) and elvitegravir (EVG) resistance. Viruses containing certain Q148 mutation profiles are associated with poor dolutegravir (DTG) treatment responses. In this study, we investigated the effect of Q148H/K/R mutations and other RAL/EVG resistance associated IN mutations on DTG…

Two Distinct Mechanisms of Resistance to Allosteric HIV-1 Integrase Inhibitors

Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of HIV-1 inhibitors. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface in the LEDGF/p75 binding pocket. Consequently, they inhibit HIV-1 IN interaction with its cellular cofactor LEDGF/p75 as well as promote aberrant IN multimerization. Selection of viral strains emerging under…